Abatacept News and Research

RSS
Abatacept (marketed as Orencia) is a fusion protein composed of an immunoglobulin fused to the extracellular domain of CTLA-4, a molecule capable of binding B7. Abatacept is a selective costimulation modulator as it inhibits the costimulation of T cells. It was developed by Bristol-Myers-Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNFa therapy.
Cochrane Systematic Review finds Abatacept effective against rheumatoid arthritis

Cochrane Systematic Review finds Abatacept effective against rheumatoid arthritis

Clinical data added to ORENCIA labeling help treat patients with rheumatoid arthritis

Clinical data added to ORENCIA labeling help treat patients with rheumatoid arthritis

Golimumab shows promise for rheumatoid arthritis

Golimumab shows promise for rheumatoid arthritis

Arthritis drug Abatacept may be effective in fighting the flu

Arthritis drug Abatacept may be effective in fighting the flu

Cimzia approved in U.S. for rheumatoid arthritis

Cimzia approved in U.S. for rheumatoid arthritis

Watery pools in bone marrow key to psoriatic arthritic damage

Watery pools in bone marrow key to psoriatic arthritic damage

Combining medications often best strategy to battle rheumatoid arthritis

Combining medications often best strategy to battle rheumatoid arthritis

Combining medications often best strategy to battle rheumatoid arthritis

Combining medications often best strategy to battle rheumatoid arthritis

New era of treatment for rheumatoid arthritis

New era of treatment for rheumatoid arthritis

Abatacept, marketed as Orencia appears to offer pain relief and increased mobility to rheumatoid arthritis patients

Abatacept, marketed as Orencia appears to offer pain relief and increased mobility to rheumatoid arthritis patients